{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:23:36Z","timestamp":1789845816141,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001735","name":"Weizmann Institute of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.bcp.2004.05.026","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T10:23:46Z","timestamp":1092479026000},"page":"981-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Phosphodiesterase inhibitors as anti-cancer drugs"],"prefix":"10.1016","volume":"68","author":[{"given":"Liron","family":"Hirsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Dantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong-Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihisa","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikazu","family":"Kotsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Amsterdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2004.05.026_BIB1","unstructured":"Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman AD, Rall TW, editors. Good man and Gilman\u2019s the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press; 1990. p. 1249\u201363."},{"key":"10.1016\/j.bcp.2004.05.026_BIB2","unstructured":"Loo TL, Freireich EJ. Cancer chemotherapeutic drugs. In: Munson PL, editor. Principles of pharmacology. New York: Chapmann & Hall; 1995. p. 1475\u20131516."},{"key":"10.1016\/j.bcp.2004.05.026_BIB3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/4.suppl_4.S41","article-title":"Carboplatin versus cisplatin","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/bi00324a025","article-title":"Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation","volume":"24","author":"Fichtinger-Schepman","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2004.05.026_BIB5","first-page":"6703","article-title":"Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells","volume":"48","author":"Sorenson","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L","article-title":"Cell cycle changes associated with formation of Pt\u2013DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity","volume":"27","author":"VaisM","year":"1997","journal-title":"Cytometry"},{"key":"10.1016\/j.bcp.2004.05.026_BIB7","first-page":"4488","article-title":"Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines","volume":"57","author":"Henkels","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB8","first-page":"227","article-title":"Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene","volume":"17","author":"Yoshida","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(02)01510-8","article-title":"Cisplatin up-regulates the adenosine A1 receptor in the rat kidney","volume":"442","author":"Bhat","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685844","article-title":"Fludarabine and gemcitibine-induced apoptosis: incorporation of analogs into DNA is a critical event","volume":"36","author":"Huang","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s002800050758","article-title":"Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells","volume":"41","author":"Cartee","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 10","key":"10.1016\/j.bcp.2004.05.026_BIB12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0093-7754(01)80011-7","article-title":"Gemcitabine in ovarian cancer","volume":"28","author":"Orlando","year":"2001","journal-title":"Semin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.bcp.2004.05.026_BIB13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(01)90274-X","article-title":"The current role of gemcitabine in ovarian cancer","volume":"28","author":"Ozols","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.coc.0000046580.51486.FF","article-title":"Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma","volume":"27","author":"Bourgeois","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdh109","article-title":"Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer","volume":"15","author":"De Lange","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/annonc\/mdh106","article-title":"Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer","volume":"15","author":"Novarino","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB18","first-page":"5107","article-title":"Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells","volume":"57","author":"Tortora","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB19","unstructured":"Rall TW. Drugs used in the treatment of asthma. In: Gilman AD, Rall TW, editors. Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press; 1990. p. 618\u201337."},{"key":"10.1016\/j.bcp.2004.05.026_BIB20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00175942","article-title":"Cyclic nucleotide phosphodiesterases in the human lung","volume":"172","author":"Dent","year":"1994","journal-title":"Lung"},{"key":"10.1016\/j.bcp.2004.05.026_BIB21","unstructured":"Barnes PJ, Mueller RA. Bronchdilators. In: Munson PL, editor. Principles of pharmacology. New York: Chapman & Hall; 1995. p. 590\u20138."},{"key":"10.1016\/j.bcp.2004.05.026_BIB22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM197810192991603","article-title":"The relation of product formulation to absorption of oral Theophylline","volume":"299","author":"Weinberger","year":"1978","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bcp.2004.05.026_BIB23","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199605233342107","article-title":"Theophylline in asthma","volume":"334","author":"Weinberger","year":"1996","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2004.05.026_BIB24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0887-2333(02)00128-5","article-title":"Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins","volume":"17","author":"Li","year":"2003","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bcp.2004.05.026_BIB25","doi-asserted-by":"crossref","unstructured":"Vanderhyden BC, Shaw TJ, Garson K, Tonary AM. In: Leung Peter CK, Adashi Eli Y, editors. Ovarian carcinoma, 2nd ed. UK: Elsevier Acadenic Press; 2004. p. 591\u2013612 [chapter 36].","DOI":"10.1016\/B978-012444562-8\/50037-9"},{"key":"10.1016\/j.bcp.2004.05.026_BIB26","doi-asserted-by":"crossref","unstructured":"Fraser M, Tsang BK. In: Leung Peter CK, Adashi Eli Y, editors. The role of X-linked inhibitor of apoptosis protein in chemoresistant ovarian cancer, 2nd ed. UK: Elsevier Acadenic Press; 2004. p. 613\u201324 [chapter 37].","DOI":"10.1016\/B978-012444562-8\/50038-0"},{"key":"10.1016\/j.bcp.2004.05.026_BIB27","doi-asserted-by":"crossref","unstructured":"Amsterdam A, Sasson R. In: Leung Peter CK, Adashi Eli Y, editors. Generation and application of ovarian steroidogenic cell lines, 2nd ed. UK: Elsevier Academic Press; 2004. p. 389\u2013409 [chapter 22].","DOI":"10.1016\/B978-012444562-8\/50023-9"},{"key":"10.1016\/j.bcp.2004.05.026_BIB28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/annonc\/mdh105","article-title":"A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer","volume":"5","author":"Sculier","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2003.09.030","article-title":"In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer","volume":"92","author":"Cloven","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","article-title":"Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated","volume":"92","author":"Papadimitriou","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2004.05.026_BIB31","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.bjc.6601498","article-title":"Docetaxel: promising and novel combinations in ovarian cancer","volume":"89","author":"Maenpaa","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2004.05.026_BIB32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1023\/A:1009614703977","article-title":"Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin","volume":"3","author":"Cartee","year":"1998","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2004.05.026_BIB33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14728214.8.1.203","article-title":"Emerging treatments for ovarian cancer","volume":"8","author":"Muggia","year":"2003","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bcp.2004.05.026_BIB34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jmv.20034","article-title":"Differential display RT-PCR analysis of ECV304 endothelial-like cells infected with dengue virus type 2 reveals messenger RNA expression profiles of multiple human genes involved in known and novel roles","volume":"72","author":"Liew","year":"2004","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.freeradbiomed.2003.11.023","article-title":"Flavonoid permeability across an in situ model of the blood-brain barrier","volume":"36","author":"Youdim","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2004.05.026_BIB36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<889::AID-IJC15>3.0.CO;2-M","article-title":"Induction of autocrine factor inhibiting cell motility from murine B16-BL6 melanoma cells by alpha-melanocyte stimulating hormone","volume":"80","author":"Murata","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2004.05.026_BIB37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-4827(03)00269-6","article-title":"Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells","volume":"289","author":"Timoshenko","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ijc.11457","article-title":"Cyclic AMP inhibits TGFbeta1-induced cell-scattering and invasiveness in murine-transformed keratinocytes","volume":"107","author":"Santibanez","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2004.05.026_BIB39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0304-3835(01)00764-9","article-title":"Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP","volume":"176","author":"Yamanaka","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2004.05.026_BIB40","first-page":"2615","article-title":"Cholera toxin triggers apoptosis in human lung cancer cell lines","volume":"57","author":"Allam","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0006-2952(98)00260-3","article-title":"Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors","volume":"56","author":"Shafer","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00054940","article-title":"Cyclic AMP decreases chemotaxis, invasiveness and lung colonization of H-ras transformed mouse fibroblasts","volume":"1","author":"Iwamoto","year":"1993","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2004.05.026_BIB43","doi-asserted-by":"crossref","unstructured":"Merimsky O, Hirsh L, Dantes A, Land-Bracha A, Suh BS, Amsterdam A. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin. 2004; in press.","DOI":"10.3892\/ijo.26.2.475"},{"key":"10.1016\/j.bcp.2004.05.026_BIB44","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1078-0432.CCR-0937-3","article-title":"Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer","volume":"10","author":"Yoh","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB45","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ijc.11585","article-title":"Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo","volume":"108","author":"Okouoyo","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2004.05.026_BIB46","first-page":"4205","article-title":"Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer","volume":"23","author":"Pectasides","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2004.05.026_BIB47","unstructured":"Bunn PA, LeChevalier T. Lung cancer research: new combinations and the emerging role of gemcitabine. Semin Oncol 1998;25(4 (Suppl 9)):1."},{"key":"10.1016\/j.bcp.2004.05.026_BIB48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.1988.6.4.633","article-title":"Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicenter randomized trial","volume":"6","author":"Rapp","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB49","doi-asserted-by":"crossref","unstructured":"NSCLC Collaborative Group: chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899\u2013909.","DOI":"10.1136\/bmj.311.7010.899"},{"key":"10.1016\/j.bcp.2004.05.026_BIB50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0962-8924(02)02294-8","article-title":"Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation","volume":"12","author":"Stork","year":"2002","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1097-2765(03)00529-X","article-title":"Regulation of p53 by Mdm2: fate is in the numbers","volume":"13","author":"Shmueli","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2004.05.026_BIB52","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1210\/endo.139.11.6280","article-title":"Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells","volume":"139","author":"Hosokawa","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.05.026_BIB53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cm.10128","article-title":"Cyclooxygenase and cAMP-dependent protein kinase reorganize the actin cytoskeleton for motility in HeLa cells","volume":"55","author":"Glenn","year":"2003","journal-title":"Cell Motil. Cytoskeleton"},{"key":"10.1016\/j.bcp.2004.05.026_BIB54","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1210\/jcem.87.7.8676","article-title":"Stimulation of apoptosis in human granulosa cells from in vitro fertilization patients and its prevention by dexamethasone: involvement of cell contact and bcl-2 expression","volume":"87","author":"Sasson","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bcp.2004.05.026_BIB55","doi-asserted-by":"crossref","first-page":"L1309","DOI":"10.1152\/ajplung.2001.280.6.L1309","article-title":"Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement","volume":"280","author":"Liu","year":"2001","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.bcp.2004.05.026_BIB56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00175942","article-title":"Cyclic nucleotide phosphodiesterases in the human lung","volume":"172","author":"Dent","year":"1994","journal-title":"Lung"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629520400351X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629520400351X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:59:30Z","timestamp":1762095570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629520400351X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S000629520400351X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2004.05.026","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase inhibitors as anti-cancer drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2004.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}